HK1200359A1 - Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof - Google Patents

Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof

Info

Publication number
HK1200359A1
HK1200359A1 HK15101049.2A HK15101049A HK1200359A1 HK 1200359 A1 HK1200359 A1 HK 1200359A1 HK 15101049 A HK15101049 A HK 15101049A HK 1200359 A1 HK1200359 A1 HK 1200359A1
Authority
HK
Hong Kong
Prior art keywords
peptide
generating
amino acid
acid residues
antibody recognizing
Prior art date
Application number
HK15101049.2A
Other languages
English (en)
Chinese (zh)
Inventor
吳稚偉
吳喜林
Original Assignee
Suzhou Naao New Material Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Naao New Material Sciences Co Ltd filed Critical Suzhou Naao New Material Sciences Co Ltd
Publication of HK1200359A1 publication Critical patent/HK1200359A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15101049.2A 2011-09-17 2015-01-30 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof HK1200359A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535988P 2011-09-17 2011-09-17
PCT/US2012/055771 WO2013040564A2 (fr) 2011-09-17 2012-09-17 Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci

Publications (1)

Publication Number Publication Date
HK1200359A1 true HK1200359A1 (en) 2015-08-07

Family

ID=47884023

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101049.2A HK1200359A1 (en) 2011-09-17 2015-01-30 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof

Country Status (7)

Country Link
EP (1) EP2755687A4 (fr)
JP (2) JP2014527085A (fr)
CN (1) CN104039350B (fr)
AU (2) AU2012308212A1 (fr)
CA (1) CA2855781A1 (fr)
HK (1) HK1200359A1 (fr)
WO (1) WO2013040564A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245313B2 (en) * 2014-10-24 2019-04-02 Versitech Limited DNA motif compounds and methods for inducing specific antibodies and cellular immunity
CN111153996B (zh) * 2020-01-10 2021-12-14 苏州睿瀛生物技术有限公司 G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011701A1 (fr) * 1993-10-26 1995-05-04 Syntello, Inc. Inhibition de l'infection des muqueuses par le vih
AU8091694A (en) * 1993-10-26 1995-05-22 United Biomedical Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US6441140B1 (en) * 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
WO2005074579A2 (fr) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Melanges de peptides a activite immunomodulatrice
BRPI0818354A2 (pt) * 2007-10-09 2017-05-16 Tech Integrale Ltd vacina preventiva do hiv baseada em anticorpos específicos para o hiv

Also Published As

Publication number Publication date
EP2755687A4 (fr) 2015-04-08
WO2013040564A3 (fr) 2013-06-27
CA2855781A1 (fr) 2013-03-21
JP2014527085A (ja) 2014-10-09
AU2017251715A1 (en) 2017-11-09
WO2013040564A2 (fr) 2013-03-21
EP2755687A2 (fr) 2014-07-23
JP2017141291A (ja) 2017-08-17
AU2012308212A1 (en) 2014-03-27
CN104039350B (zh) 2019-07-05
CN104039350A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
HK1249406A1 (zh) 芳族陽離子肽和使用它們的方法
HK1247627A1 (zh) 多特異性fab融合蛋白及其使用方法
ZA201308251B (en) Amino acid sequence presenting fusion polypeptide and its use
HK1223550A1 (zh) 芳香族陽離子肽及其用途
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
IL230918A0 (en) Modified proteins and peptides
HK1244540A1 (zh) 芳香族陽離子肽及其用途
GB2509565B (en) Photo-dissociation of proteins and peptides in a mass spectrometer
HK1197028A1 (en) Aromatic-cationic peptides and uses of same
IL229353B (en) Dolestatin derivatives related to unnatural amino acids and medicinal preparations that include them
EP2734938A4 (fr) Procédé et système de classement dans une interface-utilisateur en langage naturel
HK1201443A1 (en) Aromatic-cationic peptides and uses of same
EP3210997C0 (fr) Agents et procédés pour l'expression et la sécrétion de peptides et de protéines
IL229358A0 (en) Peptide extraction process and its use in liquid phase peptide synthesis
EP2797629A4 (fr) Anticorps humain aglycosylé et protéine de fusion, et leurs utilisations
EP2747773A4 (fr) Procédés et compositions renfermant un peptide dérivé de l'extrémité c terminale de bax
HK1200359A1 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2695892A4 (fr) Peptide pouvant induire un anticorps capable de reconnaître la stéréostructure du vih
IL234753B (en) A method for preparing a recombinant peptide and the prepared peptide
EP2680879A4 (fr) Lieurs peptidiques pour compositions de polypeptide et procédés pour les utiliser
EP2771689A4 (fr) Peptides usp2a et anticorps
EP2577537A4 (fr) Méthode de préparation d'inhibiteurs peptidiques d'une enzyme activée par des lipides et peptides produits par cette méthode
EP2754482A4 (fr) Procédé de capture de co2 et de so2
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides